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Immune thrombocytopenic purpura (ITP) is defined as an acquired thrombocytopenia with 
antibodies detected against platelet surface antigens, and it is the most common form 
of thrombocytopenia in otherwise asymptomatic adults. ITP secondary to an underlying 
condition is a diagnosis of exclusion that is essential to establish for treatment efficacy. 
Secondary thrombocytopenia caused by cytomegalovirus (CMV) is common; however, 
case reports associated with diagnosis in immunocompetent adults are rare, and to 
the best of our knowledge only 20 publications have been associated with this diagno-
sis. Our report is based on a clinical presentation of a 37-year-old female complaining 
of petechiae, heavy menses, shortness of breath, and a platelet count of 1 ×  109/L. 
Treatment with IVIG and steroids failed to improve platelet count. Subsequently, an infec-
tious laboratory workup was performed, detecting CMV infection, and treatment with 
antiviral agents was initiated, causing platelet count to increase as viral load decreased.
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INtRoDUCtIoN
Immune thrombocytopenic purpura (ITP) is a form of acquired thrombocytopenia triggered by 
anti-platelet antibodies that destroy platelets peripherally, damage megakaryocytes, and inhibits 
platelet production in the marrow (1). Agents such as CMV, hepatitis C, Epstein–Barr virus, and 
Parvovirus B19, among others, have been identified as the culprits behind this form of ITP (2). 
Steroids and IVIG are the treatment of choice for ITP. The primary infection should be treated 
in order to allow ITP standard therapies to be effective. We present a case of a 37-year-old female 
patient with a history of petechia, heavy menstrual bleed, and low platelets (1 × 109/L) after a CMV 
infection. Cytomegalovirus (CMV) is a known cause of morbidity and mortality in patients with 
immunosuppressed states, whereas in the immunocompetent patients, the virus commonly mani-
fests as an asymptomatic infection or as mononucleosis-like syndrome. CMV can cause disease in 
immunocompromised patients either via a primary CMV infection or reactivation of a latent CMV 
infection. It is characterized by malaise, myalgia, headache, sore throat, and fever. Associated clinical 
syndromes include encephalitis, pneumonitis, hepatitis, uveitis, retinitis, colitis, and graft rejection. 
Treatment of the primary infection is imperative because standard therapies for ITP regain their 
efficacy once the infection is resolved (3).
taBLe 1 | Complete blood count (CBC) with differential during the course of the disease.
admission Day 2 Day 3 Day 5 Day 10 Day 30 3 months Follow-up
WBC (103/μL) 5.6 9.4 6.6 9.2 9 10.6 8.7
RBC (106/μL) 4.41 3.92 3.55 3.25 3.27 3.94 4.18
Hgb (g/dL) 13.7 12.1 10.7 10.4 10 11.8 12.3
Hct (%) 40.9 35.8 32.9 32 30.6 37.7 39.6
RDW (%) 12.7 12.8 12.9 13.3 13.5 14.4 14.9
Neutrophil (%) 42 77.4 74.2 65.6 71.9 73.5 55.8
Lymphocyte (%) 46 19 21.5 23.4 15 20.4 30.8
Monocyte (%) 8.4 1.4 3.5 7.8 10.9 4.1 11.2
Eosinophil (%) 1.1 0 0 0 0 0.2 0.3
Basophil (%) 1.4 0.5 0.2 0.5 0.4 0.2 0.3
Immature granulocyte (%) 1.1 1.7 1.2 2.7 1.8 2 1.6
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Case pReseNtatIoN
A 37-year-old female presented to the emergency department 
complaining of shortness of breath, pruritic rash, epistaxis, heavy 
menses, and night sweats. A physical examination revealed a 
petechial rash on her torso, lower extremities, and oral mucosa. 
On admission, the patient was found to have platelet count of 
1.0 × 109/L (Figure 1).The normal range for platelets in healthy 
Caucasians is 150,000–400,000/mm3 (a cubic millimeter equals a 
microliter), or 150–400 × 109/L (4). The patient’s vitals were stable, 
including the absence of fever, and on physical examination no 
splenomegaly was found. White blood cells (WBC) and red blood 
cells (RBC) were unremarkable (Table  1); nonetheless, a slight 
elevation in AST and ALT was found. The patient’s symptoms 
aroused suspicion of immune thrombocytopenia. Initial admin-
istration of high-dose steroids (dexamethasone 40 mg PO ×4 days 
and prednisone 60 mg PO ×2 days) showed improvement in the 
patient’s platelet count; however a subsequent course of high-dose 
methylprednisolone (solumedrol 60 mg IV ×3 days) did not show 
any further clinical benefit. Intravenous Immunoglobulin (IVIG 
1 g/kg ×2 days) was administered, and far from alleviating existing 
FIGURe 1 | platelet count before and after treatment. Graph 
representing the trend of platelet count from the time of admission to the 
post treatment period with valgancyclovir, romiplostim, and IVIG.
symptoms, caused right pleural effusion, prompting its discon-
tinuation and the possibility of secondary ITP was suspected. An 
infectious work up was performed, and results were all negative 
except by PCR for CMV–DNA that showed CMV IgM more 
than fourfold, a viral load of 46,881 copies/MI (Figure 2). A bone 
marrow biopsy revealed a combined pattern of normocellular and 
hypercellular areas along with the presence of megakaryocytes. Per 
Infectious Disease and Hematology-Oncology medical team rec-
ommendations, a combination of valgancyclovir (900 mg PO BID) 
and romiplostin (Nplate® 1 μg/kg SC/week) was started, causing a 
significant drop in viral load (Figure 2). Resolution of CMV infec-
tion and subsequent promotion of platelet growth contributed to 
a significant improvement in patient’s symptoms. The patient was 
discharged with a platelet count of 49 ×  109/L (Figure  1). One 
month later, platelet count improved to 228 × 109/L, and CMV viral 
load dropped to <200 copies/MI and asymptomatic (Figure 2).
INFoRMeD CoNseNt stateMeNt
The subject described in this report has given verbal informed 
consent. Written informed consent is not required if data is drawn 
from observed behavior or if data does not contain identifying 
information, as it is in the present report.
DIsCUssIoN
Secondary ITP is an acquired thrombocytopenia caused by 
autoantibodies against platelets (5). Initial presentations of ITP 
are petechiae and purpura, with a more severe progression to 
intracranial hemorrhage or gastrointestinal bleeding, leading 
to a fatal outcome, if treatment is not started on a promptly 
manner (3, 5). Chronic conditions, such as systemic lupus 
erythematosus (SLE), chronic lymphocytic leukemia (CLL), 
and infectious agents such as immunodeficiency virus (HIV), 
hepatitis C virus (HCV), and CMV, can trigger this form of 
ITP (5–7). The various theories of CMV infection-induced 
thrombocytopenia were described by Crapnell et  al., as 
CMV-induced direct cytotoxicity to hematopoietic cells with 
immune-mediated destruction of infected cells or impairment 
of bone marrow stromal function (7).
Immune thrombocytopenic purpura is frequently an exclu-
sionary diagnosis, characterized by the absence of any other 
FIGURe 2 | Viral load before and after treatment. Viral load in copies/MI 
for Cytomegalovirus (CMV) measured at admission, post treatment with 
valgancyclovir and during follow-up.
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clinical condition accountable for the low platelet count and 
isolated thrombocytopenia. Generally, risk of bleeding in ITP is 
low, but it increases when platelet count is <10 × 109/L. Initial 
treatment should focus on preventing clinically significant 
bleeding and treating the primary infection, rather than to 
normalize platelet count, as the risk of bleeding is low even in 
patients with severely low platelet counts (5). Some physicians 
believe treatment with steroids should be avoided in patients 
with CMV-induced thrombocytopenia, as immunosuppressive 
treatment may be responsible for the primary CMV infection 
exacerbation and trigger further decrease in platelet count (3, 
8). It has been demonstrated that standard therapies for ITP, 
including IVIG and splenectomy, regain their efficacy once the 
primary CMV infection is controlled with antiviral agents such as 
ganciclovir or valganciclovir (3, 9). Treatment with ganciclovir or 
valganciclovir is currently recommended as first-line treatment 
for immunecompromised adults with severe CMV disease, and 
few studies have evaluated the use of these antiviral drugs for 
treatment in immunocompetent adults due to the major side 
effects of these agents such as myelosupression (10). Nevertheless, 
untreated CMV disease in immunocompetent adults is associ-
ated with increased morbidity and mortality. There are some 
studies that provide evidence of significant clinical improvement 
after treatment with antiviral agents is started (10–13). On the 
other hand, the use of thrombopoeitin receptor (TPO-R) agonists 
such as romiplostin (Nplate®) has been studied, and literature has 
shown that these agents are effective in refractory ITP compared 
to placebo (14–16).
CoNCLUsIoN
Our case report will add to the existing body of research and will 
increase awareness of this form of thrombocytopenia. Further 
research is needed in order to establish general treatment guide-
lines for CMV-induced thrombocytopenia in immunocompetent 
patients while steroids administration is still debatable.
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